Why Are Viridian Therapeutics Shares Falling Today
Portfolio Pulse from Vandana Singh
Viridian Therapeutics Inc (NASDAQ:VRDN) shares are falling after the company released preliminary data from its ongoing Phase 1/2 trial of VRDN-001 for chronic thyroid eye disease (TED). The data showed clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001. However, none of the patients treated with VRDN-001 achieved complete resolution of diplopia at week 6, which could be causing investor concern. The company also provided updates on its THRIVE Phase 3 trial and subcutaneous (SC) program candidates in TED.
July 11, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Viridian Therapeutics shares are falling due to concerns over preliminary trial data for VRDN-001. The lack of complete resolution of diplopia at week 6 may be causing investor concern.
The stock price of Viridian Therapeutics is falling due to investor concerns over the preliminary data from the Phase 1/2 trial of VRDN-001 for chronic thyroid eye disease. Despite showing clinically meaningful and rapid improvement in signs and symptoms, the lack of complete resolution of diplopia at week 6 is likely causing investor concern.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100